What is the massive transfusion protocol (MTP) and how is it initiated and managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Massive Transfusion Protocol (MTP)

A massive transfusion protocol is a pre-established, coordinated hospital-wide system that rapidly delivers blood products in fixed ratios (typically 1:1:1 for plasma:platelets:red blood cells) to patients with life-threatening hemorrhage, activated by a designated team leader when massive bleeding is identified or anticipated. 1

Definition and Activation

Massive transfusion is traditionally defined as transfusion of >10 units of packed red blood cells (pRBCs) within 24 hours, though this occurs in <2% of civilian trauma patients 2. Hospitals must have a major hemorrhage protocol in place that includes clinical, laboratory, and logistic responses 1.

Who Activates the Protocol

The team leader (usually the consultant or most senior physician at the scene) declares the massive hemorrhage situation and directs patient management 1. This can be triggered in two scenarios:

  • Warning scenario: Patient en route with history suggesting massive bleeding (trauma, obstetric emergency, major surgery, coagulopathy)
  • Active bleeding scenario: Patient already hemorrhaging with physiologic decompensation 1

Immediate Actions Upon Activation

When MTP is activated, execute these steps simultaneously 1:

  1. Control obvious bleeding (pressure, tourniquet, hemostatic dressings)
  2. Administer high-flow oxygen
  3. Establish large-bore IV access (ideally 8-Fr central access in adults; consider intraosseous if peripheral fails)
  4. Draw baseline labs: FBC, PT, aPTT, Clauss fibrinogen (NOT derived fibrinogen), and cross-match
  5. Initiate near-patient testing (TEG/ROTEM if available)
  6. Begin fluid resuscitation with warmed blood products (Type O blood fastest, then type-specific, then cross-matched)
  7. Actively warm the patient and all fluids
  8. Alert surgical/interventional radiology teams and arrange for cell salvage 1

Blood Product Ratios: The Core Controversy

Current Recommendation

For initial resuscitation in trauma patients with massive hemorrhage, use either: 3

  • Fixed high-ratio strategy: 1:1:1 ratio (plasma:platelets:pRBCs) with platelets administered in the first transfusion pack, OR
  • At minimum 1:2 ratio (FFP:pRBC) 3

This represents a paradigm shift from older protocols that used 1:4 ratios. Military data from Iraq War combat hospitals showed casualties receiving FFP:RBC ratios of 1:4 or lower had three-fold higher mortality compared to those receiving 2:3 ratios 2. The PROPPR trial (680 trauma patients) demonstrated that 1:1:1 ratios achieved improved hemostasis and reduced exsanguination deaths compared to 1:1:2 ratios, though overall mortality was comparable 3, 4.

Important Caveat

This high-ratio evidence is strongest for trauma patients 4. The evidence for fixed high-ratio transfusion in non-traumatic bleeding (obstetric, surgical, medical) is insufficient to make firm recommendations, though many centers extrapolate trauma protocols to all bleeding scenarios 4, 5. In fact, 58% of adult and 65% of pediatric MTP activations are for non-trauma indications 5.

Blood Component Dosing

Fresh Frozen Plasma (FFP)

  • Initial dose: 10-15 mL/kg 2
  • Further doses guided by coagulation monitoring and other blood products administered
  • Risks include TRALI (transfusion-related acute lung injury), circulatory overload, infections 2, 6

Alternative Strategy: Coagulation Factor Concentrates

European centers increasingly favor fibrinogen concentrate or cryoprecipitate plus pRBCs as first-line therapy rather than FFP 3. Critical fibrinogen levels (<1.5 g/L) occur early in massive trauma, and FFP cannot practically raise fibrinogen >1.5-1.8 g/L due to volume constraints 3.

Essential Equipment and Logistics 1

Team Roles

  • Communications lead: Sole role is coordinating with laboratories and departments
  • Blood runner: Porter/healthcare worker in constant radio communication to transport samples and products
  • IV access specialist: Dedicated to securing and maintaining vascular access 1

Required Equipment

  • Blood warmers: All IV fluids ≥500 mL and blood components must be warmed to 37°C using approved devices with visible thermometers and audible alarms 1
  • Administration sets: 170-200 μm filters for all blood components
  • Rapid infusion devices: Capable of 6-30 L/hour with integrated warming
  • Pressure devices: For emergency rapid administration with large-gauge access 1

Critical pitfall: Never improvise warming (no microwaves, radiators, or warm water baths) 1

Platelet-Specific Considerations

Use a clean 170-200 μm giving set for platelets—one previously used for red cells will cause platelets to adhere to residual RBCs, reducing effective dose 1. While special platelet sets are ideal, they're unnecessary in massive hemorrhage emergencies 1.

Early platelet transfusion (within 4-6 hours) is associated with decreased 24-hour and 30-day mortality without increased ARDS or multiorgan failure, though wound infections may increase 3.

Antifibrinolytic Therapy

Tranexamic acid should be administered when accelerated fibrinolysis is identified (via TEG/ROTEM or elevated D-dimers/fibrin degradation products) 1:

  • Loading dose: 1 g IV over 10 minutes
  • Maintenance: 1 g IV over 8 hours

This is supported by the CRASH-2 trial 1. Contraindication: Subarachnoid hemorrhage (risk of cerebral edema and infarction). Use cautiously in renal impairment 1.

Monitoring and Termination

Continue MTP until:

  • Normal physiologic parameters are restored
  • Definitive bleeding control is achieved
  • Coagulation parameters normalize 7

Ongoing assessment must include 1:

  • Injury patterns and obvious blood loss (clothes, floor, drains)
  • Signs of internal bleeding
  • Physiologic parameters (skin color, heart rate, BP, capillary refill, consciousness)

Common pitfall: Some patients compensate well despite significant blood loss—don't be falsely reassured by initially stable vital signs 1.

Viscoelastic Testing (TEG/ROTEM)

While viscoelastic hemostatic assays provide real-time clot assessment for individualized treatment 8, the ITACTIC trial showed no overall survival benefit when comparing viscoelastic-guided versus conventional lab-guided transfusion, except in traumatic brain injury patients who had reduced 28-day mortality 3. Both groups received similar 1:1:1 initial resuscitation 3.

Special Populations

Pediatric Patients

  • Minimize blood loss and donor exposure
  • Use pediatric components when readily available
  • Same principles apply but with weight-based dosing 1
  • Specific pediatric MTPs should be developed 9

Obstetric Hemorrhage

50% of hospitals with multiple MTPs have obstetric-specific protocols, and these are more likely to include cryoprecipitate or fibrinogen concentrate in the first round (50% vs. 14% in general MTPs) 5.

Key Implementation Points

Each hospital must develop its own MTP adapted to local infrastructure, logistics, and patient populations 1, 7. The protocol should be regularly practiced through interprofessional simulations to ensure team readiness 10. Success depends not just on blood product ratios, but on the coordinated, efficient response that standardized protocols provide 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.